×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Justin Chura, MD, and Anya Khomenko, survivor of ovarian cancer, reinforce the value in patient education and reflect on the importance of seeking a second opinion from an expert in ovarian cancer prior to beginning therapy.
Justin Chura, MD, discusses the role of the gynecologic oncologist in establishing an initial treatment plan for newly diagnosed patients with ovarian cancer and helping patients, such as Anya Khomenko, prepare for every step along the way.
Justin Chura, MD, and Anya Khomenko, survivor of cancer, remark on later-stage diagnoses in ovarian cancer and the wide range of nonspecific symptoms that can occur, advising viewers to pay attention to warning signs.
Anya Khomenko, survivor of ovarian cancer, explains how she believed she would soon die following her diagnosis. Justin Chura, MD, highlights how the outlook has improved for patients.
Kelly Irvin
Should I be planning big, celebratory trips or my funeral? My fears may not be rational, but they're real.
Beth Fand Incollingo
Recent findings that the most common kind of ovarian cancer may start in the fallopian tubes could have implications for the prevention, diagnosis and treatment of the disease subtype. 
Oliver Dorigo, M.D., Ph.D.
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond.
Kelly Irvin
No matter how cancer makes you look, you’re still you—a better you.
 
Oliver Dorigo, M.D., Ph.D.

Oliver Dorigo, M.D., Ph.D., associate professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses the lack of effective screening methods for ovarian cancer.
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable